Anavex Life Sciences Q2 EPS $(0.06) Beats $(0.08) Estimate
Anavex Life Sciences Corp AVXL
$2.75
▲ +1.85%
(+$0.05)
⬆️ Above Yest. High
🗓️ Earnings Next Week
Open
$2.67
Prev Close
$2.70
Day Range
$2.66 – $2.77
52W Range
$2.26 – $12.68
Market Cap
$254.85M
Beta
1.15
EPS (TTM)
$-0.46
📋 Company Profile
| Industry | Biotechnology |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 2006-04-13 |
| Shares Out. | 92,670,000 |
| Website | anavex.com ↗ |
| Phone | 18446893939 |
| Employees | 34 |
| Net Income | -$5.7M |
| Total Assets | $133.0M |
| Total Liabilities | $6.4M |
| Equity | $126.6M |
About Anavex Life Sciences Corp
Anavex Life Sciences Corp is a clinical stage biopharmaceutical company engaged in the development of differentiated therapeutics by applying precision medicine to central nervous system(CNS) diseases with high unmet need. It analyzes genomic data from clinical trials to identify biomarkers, which are used in the analysis of its clinical trials for the treatment of neurodegenerative and neurodevelopmental diseases. The company focuses on developing treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders. Its pipeline includes ANAVEX 2-73 and ANAVEX 3-71 and several other compounds in different stages of clinical and pre-clinical development.
Anavex Life Sciences Corp is a publicly traded company under the ticker symbol AVXL on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
7 analysts (2026-07-01)